Gilead Sciences, Inc. (GILD) — closed signal from September 6, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 5, 2025.
Predicted vs. what happened
What happened
Reached its target in 74 days.
The thesis — published September 6, 2025
Gilead is taking smart steps that can support long-term growth. It bought Interius to advance treatments that program cells inside the body, and teamed up with PEPFAR to bring its HIV drug lenacapavir to more people. Broad rating models like its fundamentals. Recent trading hints more steady buying than usual, but signals are still soft, so buy near $114-116 and consider adding only if the price turns up with stronger activity in the next 3 months.
Primary drivers
- Buying Interius adds new cell therapies and broadens future options
- PEPFAR deal should expand access to lenacapavir in more countries
- Strong scores on broad fundamentals suggest a solid base for growth
- Trading shows steadier buying than usual, a constructive sign
How it played out
GILD: target reached in 74 days
Lyra published GILD at $113.51 on 2025-09-06 with expected growth of 12%. The thesis pointed to the Interius purchase, the PEPFAR lenacapavir access deal, strong broad fundamentals, and steadier buying than usual. It also said the signals were still soft.
Inside the window, the stock reached the $125.42 target in 74 days. It peaked at $127.86 on 2025-11-20, a 12.6% gain. By 2025-12-05, it ended at $120.42. The thesis played out. It reached the target before the window closed, then gave back part of the move.
What happened during the window
On 2025-09-24, The Guardian reported deals for lower-cost lenacapavir supplies in 120 low- and middle-income countries. On 2025-10-31, Investor's Business Daily reported Gilead's third-quarter results and wrote that the company raised the lower end of its 2025 guidance.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.